SMARCB1 and sarcoma: In mice, whereas homozygous inactivation leads to early embryonic lethality, heterozygous loss promotes the development of undifferentiated or poorly differentiated sarcomas consistent with MRT observed in infants [28,29,30], highlighting the central role of SMARCB1 in this disease.